(S)-5-(4-(1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methylphenyl]-propyl)-2-methylphenoxymethyl)dihydrofuran-2-one | 865235-94-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-5-(4-(1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methylphenyl]-propyl)-2-methylphenoxymethyl)dihydrofuran-2-one
• 英文别名: (S)-5-(4-{1-ethyl-1-[4-((E)-3-hydroxy-pent-1-enyl)-3-methyl-phenyl]-propyl}-2-methyl-phenoxymethyl)-dihydro-furan-2-one；(S)-5-(4-{1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-pent-1-enyl)-3-methyl-phenyl]-propyl}-2-methyl-phenoxymethyl)-dihydro-furan-2-one；(5S)-5-[[4-[3-[4-[(E)-3-ethyl-3-hydroxypent-1-enyl]-3-methylphenyl]pentan-3-yl]-2-methylphenoxy]methyl]oxolan-2-one
• CAS: 865235-94-5
• 化学式: C₃₁H₄₂O₄
• 分子量: 478.672
• InChiKey: PWDFJKWIIXDWJW-FOHRATBMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-5-(4-(1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methylphenyl]-propyl)-2-methylphenoxymethyl)dihydrofuran-2-one 在 氢氧化钾 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 以85%的产率得到(S)-5-(4-{1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-pent-1-enyl)-3-methyl-phenyl]-propyl}-2-methyl-phenoxy)-4-hydroxy-pentanoic acid potassium salt
  参考文献：
  名称：

  [EN] BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS
  [FR] COMPOSES DE BISPHENYLE UTILES EN TANT QU'AGONISTES DE RECEPTEURS DE LA VITAMINE D3

  摘要：

  公开号：

  WO2005087700A3
• 作为产物：
  描述：

  4-[1-ethyl-1-(4-ethynyl-3-methylphenyl)-propyl]-2-methylphenol 在 正丁基锂 、 potassium carbonate 、 红铝 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 21.0h， 生成 (S)-5-(4-(1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methylphenyl]-propyl)-2-methylphenoxymethyl)dihydrofuran-2-one
  参考文献：
  名称：

  Systematic SAR study of the side chain of nonsecosteroidal vitamin D3 analogs

  摘要：

  A series of nonsecosteroidal vitamin D-3 analogs with carboxylic acid were explored. Through our systematic SAR studies on the side chain moiety, compound 6b was identified as the optimal compound showing excellent vitamin D receptor (VDR) agonistic activity. Compound 6b had the diethyl group in the terminal which was bound by (E)-olefin linker to the bisphenyl core. Calculating the volume of the side chain showed that the diethyl group in 6b filled the hydrophobic region of VDR with the ideal packing coefficient based on the 55% rule, and that this resulted in the most potent in vitro activity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.05.023

文献信息

• Bisphenyl compounds useful as vitamin D3 receptor agonists
  申请人：Wallace David

  公开号：US20060025474A1

  公开（公告）日：2006-02-02

  The present invention discloses bisphenyl compounds of the formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W are defined herein after. These compounds are useful as pharmaceuticals.

  本发明公开了以下式子的双苯基化合物：其中R1，R2，R3，R4，R5，R6，X，Y，W的定义见下文。这些化合物可用作药物。
• BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1740522A2

  公开（公告）日：2007-01-10
• [EN] BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS<br/>[FR] COMPOSES DE BISPHENYLE UTILES EN TANT QU'AGONISTES DE RECEPTEURS DE LA VITAMINE D3
  申请人：CHUGAI PHARMACEUTICAL CO LTD

  公开号：WO2005087700A3

  公开（公告）日：2006-10-19
• Systematic SAR study of the side chain of nonsecosteroidal vitamin D3 analogs
  作者：Hirotaka Kashiwagi、Yoshiyuki Ono、Masateru Ohta、Kenji Morikami、Tadakatsu Takahashi

  DOI：10.1016/j.bmc.2012.05.023

  日期：2012.7

  A series of nonsecosteroidal vitamin D-3 analogs with carboxylic acid were explored. Through our systematic SAR studies on the side chain moiety, compound 6b was identified as the optimal compound showing excellent vitamin D receptor (VDR) agonistic activity. Compound 6b had the diethyl group in the terminal which was bound by (E)-olefin linker to the bisphenyl core. Calculating the volume of the side chain showed that the diethyl group in 6b filled the hydrophobic region of VDR with the ideal packing coefficient based on the 55% rule, and that this resulted in the most potent in vitro activity. (C) 2012 Elsevier Ltd. All rights reserved.